Clinical trials: Advanced Cervical Carcinoma
Head and Neck Cancer
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma
Two different patient populations will be targeted for this study. The first population (SP1) will include patients with recurrent/metastatic head and neck cancers, excluding salivary gland carcinomas.
- Trial name
- NCT00228488
- Testing
- Gefitinib
- Where
- 2 sites in Hong Kong, Singapore
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Oral Mucositis
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers.
- Trial name
- KEVLARx (NCT05966194)
- Testing
- RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2
- Where
- 14 sites in United States
- Volunteers
- 216 people
- Sponsor
- EpicentRx, Inc.
Head and Neck Cancer, Oral Cavity Cancer
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate if the addition of valproic acid to standard platinum-based chemoradiation as definitive treatment of locally advanced Head and Neck squamous cell carcinoma can improve treatment outcomes…
- Conditions
- Head and Neck Cancer, Oral Cavity Cancer, Oropharyngeal Cancer
- Trial name
- NCT01695122
- Testing
- Valproic Acid
- Where
- Brazil
- Volunteers
- 14 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV
Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN
This multicentre, randomised Phase II Pilot Study evaluates the efficacy of docetaxel, cisplatin and 5-fluorouracil or Cetuximab, followed by Cetuximab with radiotherapy.
- Conditions
- Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV, Squamous Cell Carcinoma of the Larynx Stage III, Squamous Cell Carcinoma of the Larynx Stage IV
- Trial name
- HNO-2 (NCT01884259)
- Testing
- Docetaxel, Cisplatin, 5-fluorouracil
- Where
- 8 sites in Austria
- Volunteers
- 100 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Nasopharyngeal Carcinoma
S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
This study is a prospective phase II trial which is designed to evaluate the efficacy and safety of IMRT combined with S-1 CCRT for locally advanced NPC.
- Trial name
- NCT03668366
- Testing
- S-1
- Where
- China
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
This is a Phase II, open-label, single-arm, multicenter study evaluating the safety and efficacy of combining Tislelizumab with induction chemoradiotherapy (CRT), followed by conversion surgery, in patients with locally advanced…
- Trial name
- NCT07039162
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- 8 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Ming-Yu Lien
Locally Advanced Cancer, Cervical Cancer
Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer
This is a mutlicentric, open-label non-randomized, national, 2-stage phase II trial to assess efficacy and safety of a weekly Carboplatin-Paclitaxel adjuvant chemotherapy after intensity modulated extended-field chemoradiation in…
- Trial name
- ACCRAPAN (NCT04016142)
- Testing
- Carboplatin-Paclitaxel adjuvant chemotherapy
- Where
- 6 sites in France
- Volunteers
- 21 people
- Sponsor
- Centre Oscar Lambret
Head and Neck Cancer, Radiotherapy
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at a locally advanced stage, where cisplatin-based chemoradiotherapy is standard but still results in high recurrence rates.
- Conditions
- Head and Neck Cancer, Radiotherapy, Anti-PD-1/CTLA-4 Antibody
- Trial name
- NCT07447570
- Testing
- Iparomlimab and Tuvonralimab injection, Hypofractionated Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Head and Neck Squamous Cell Carcinoma
Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC
This study is a prospective, open-label, single-arm study. The trial will be divided into 3 phases: screening/baseline, treatment and follow-up.
- Trial name
- NCT05351762
- Testing
- Nimotuzumab Combined With Neoadjuvant Chemotherapy
- Volunteers
- 55 people
- Sponsor
- Xijing Hospital
Oral Cancer
Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer
The goal of this observational study is to investigate the effectiveness of neoadjuvant chemoimmunotherapy (NACI) regimens in treating advanced oral squamous cell carcinoma (OSCC) patients.
- Trial name
- HNC-SYSU-005 (NCT06143761)
- Testing
- PD-1 inhibitor+carboplatin+albumin-bound paclitaxel
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in…
- Conditions
- Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck, Colorectal Adenocarcinoma, Metastatic Solid Tumor
- Trial name
- NCT04474470
- Testing
- NT219, NT219 and ERBITUX® - Dose Escalation, NT219 and ERBITUX® - Expansion
- Where
- 10 sites in United States, Israel
- Volunteers
- 52 people
- Sponsor
- TyrNovo Ltd.
Solid Tumor
A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects with Advanced Solid Malignancies
- Trial name
- innovaTV 206 (NCT03913741)
- Testing
- tisotumab vedotin
- Where
- 8 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Genmab
Esophagus Cancer
Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting
It is reported that compared to chemotherapy alone, immunochemotherapy has significantly improved the overall survival of patients with advanced metastatic ESCC.
- Trial name
- RICE-Chronos (NCT05615129)
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Guangdong Provincial People's Hospital
Advanced Solid Tumors
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select…
- Trial name
- NCT04943900
- Testing
- BMS-986416, Nivolumab
- Where
- 19 sites in United States, Argentina and 5 more
- Volunteers
- 67 people
- Sponsor
- Bristol-Myers Squibb
Head Neck Cancer Squamous Cell Metastatic, Head Neck Cancer Squamous Cell Recurrent
Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and Neck
This study is to evaluate disease control rate (DCR) at 8 weeks of BKM120 administered as therapy for patient with recurrent/metastatic head and neck squamous cell carcinoma.
- Trial name
- NCT01527877
- Testing
- BKM120
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Yonsei University
Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma
Neoadjuvant Immunochemotherapy for LAOSCC
To evaluate the prognostic efficacy of neoadjuvant immunochemotherapy with tislelizumab, albumin paclitaxel and cisplatin followed by radical surgery and adjuvant therapy compared with standard therapy for patients with locally…
- Trial name
- NCT06258811
- Testing
- albumin paclitaxel, cispatin, tislelizumab
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Lai-ping Zhong
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
This study will evaluate the efficacy and safety of atezolizumab compared with placebo as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck…
- Trial name
- IMvoke010 (NCT03452137)
- Testing
- Atezolizumab
- Where
- 135 sites in United States, Australia and 21 more
- Volunteers
- 406 people
- Sponsor
- Hoffmann-La Roche
Esophageal Squamous Cell Carcinoma
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
In this study, participants with histologically diagnosed locally advanced esophageal squamous cell carcinoma who have received preoperative cisplatin-based chemoradiotherapy followed by surgery harbouring high risk of tumor…
- Trial name
- NCT03322267
- Testing
- Pembrolizumab
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
Esophageal Squamous Cell Carcinoma
Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma
The purpose of this study is to determined the best definitive radiotherapy dosage for patients with locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT03790553
- Testing
- Radiotherapy
- Where
- 3 sites in China
- Volunteers
- 646 people
- Sponsor
- Fudan University
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors.
- Conditions
- Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT05039801
- Testing
- Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center